"Medicare was built on evidence-based medicine," said Duane Boise, CEO of MMJ International Holdings. "If cannabinoid therapies are going to be reimbursed by federal healthcare programs, they should meet the same scientific standards every other drug must meet-rigorous clinical trials, validated manufacturing, and FDA oversight."
WASHINGTON, DC / ACCESS Newswire / March 10, 2026 / Why All CBD Is Not the Same - And Why FDA Standards Matter
As federal policymakers debate the proposed Medicare CBD pilot program, a critical scientific reality is often overlooked: not all CBD products are the same.
While cannabidiol (CBD) is a single chemical compound, the products sold across the consumer marketplace vary dramatically in purity, formulation, manufacturing quality, and safety. These differences are precisely why the United States established a rigorous drug approval system administered by the U.S. Food and Drug Administration.
Without those standards, two products labeled "CBD" may behave very differently in the body.
This issue becomes particularly significant as policymakers consider reimbursing cannabinoid products for seniors through federal healthcare programs.
Plant Chemistry Is Highly Variable
CBD is derived from Cannabis sativa, a plant with thousands of genetically distinct varieties. Each cultivar produces a different chemical profile containing:
cannabinoids such as CBD, THC, CBG, and CBC
aromatic terpenes
flavonoids
plant waxes and lipids
In consumer products, cannabinoid ratios can vary widely from batch to batch. That variability affects both therapeutic response and safety, especially for older adults managing chronic pain, neurological disorders, or multiple medications.
Pharmaceutical drug development requires genetically stable plant sources and reproducible chemical profiles so that every batch of medicine is chemically identical.
Manufacturing Methods Matter
CBD products are created by extracting compounds from cannabis plant material. The extraction and purification process determines whether the final product contains unwanted contaminants.
Possible contaminants include:
pesticides used during cultivation
residual solvents from extraction processes
heavy metals absorbed from soil
microbial contaminants such as mold or bacteria
Pharmaceutical manufacturers must follow Good Manufacturing Practice (GMP) standards to ensure contaminants remain below strict safety thresholds.
Many consumer CBD products are not produced under these pharmaceutical controls.
Label Accuracy Is Often Unreliable
Multiple academic studies have shown that retail CBD products frequently contain cannabinoid levels that differ substantially from what appears on the label.
Some products contain far less CBD than advertised, while others contain measurable levels of THC despite being marketed as THC-free.
For patients and physicians, inconsistent potency creates a fundamental problem: it becomes impossible to establish reliable dosing.
Dosing Requires Clinical Validation
Approved medications undergo extensive testing to determine:
safe dosage ranges
pharmacokinetics (how the drug is absorbed and metabolized)
drug interactions
long-term safety
The only FDA-approved cannabidiol medicine, Epidiolex, underwent years of clinical trials before physicians could prescribe it.
Most retail CBD products, by contrast, have no clinically validated dosing guidelines, particularly for older adults already taking multiple medications.
Stability and Consistency
Cannabinoids degrade over time when exposed to heat, oxygen, or light. Without stability testing, the potency of CBD products can change during storage.
FDA drug approval requires stability studies conducted under international guidelines to ensure that:
potency remains consistent
degradation products remain safe
shelf life is clearly defined
These safeguards are rarely present in consumer CBD products.
The Role of the FDA Drug Approval System
For more than a century, the United States has relied on a simple principle in medicine:
Products that claim to treat disease must prove they are safe and effective.
That proof requires:
Investigational New Drug (IND) authorization
controlled clinical trials
validated manufacturing processes
FDA review of safety and efficacy
These requirements exist to protect patients from contaminated, ineffective, or mischaracterized treatments.
Why This Matters for Medicare
If a federal reimbursement program begins funding CBD products that have not undergone FDA review, it raises a fundamental policy question.
Without standardized formulations, validated dosing, and pharmaceutical manufacturing controls, researchers may struggle to determine whether patient outcomes reflect:
the cannabinoid itself
inconsistent product quality
placebo effects
interactions with other medications
In other words, reimbursement without standards risks substituting experimentation for evidence-based medicine.
A Crossroads for Cannabinoid Medicine
The debate surrounding Medicare's CBD pilot program reflects a broader crossroads for the cannabinoid industry.
One path treats cannabinoids primarily as consumer wellness products-widely available but produced with varying standards and inconsistent formulations.
The other path treats cannabinoids as medicines, subject to the same scientific rigor required of every other therapeutic used in modern healthcare.
Companies pursuing the pharmaceutical pathway, including organizations such as MMJ International Holdings, have invested years advancing cannabinoid therapies through the FDA drug development framework-conducting clinical trials, validating formulations, and building pharmaceutical manufacturing standards.
That process is deliberately demanding. It ensures that when patients receive a treatment, physicians can rely on verified safety, validated dosing, and consistent product quality.
The Bottom Line
CBD as a molecule may be identical across products.
But the quality, purity, formulation, and safety of CBD products can differ dramatically depending on how they are cultivated, manufactured, and tested.
The FDA approval process exists to eliminate those uncertainties.
As cannabinoid therapies move closer to mainstream medicine, maintaining those standards will determine whether the industry evolves into a legitimate pharmaceutical sector-or remains a loosely regulated consumer marketplace.
Madison Hisey
MHisey@mmjih.com
203-231-85832
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/the-30-billion-cbd-question-should-medicare-reimburse-cannabis-produc-1146048
